Sapu BioScience and Cromos Pharma initiating P201 – A
AGOURA HILLS, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced...
Source: globenewswire.com
Page 8 - Randomized Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Randomized Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Randomized Phase Today - Breaking & Trending Today
Sapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer
AGOURA HILLS, Calif., Aug. 23, 2023 -- Oncotelic Therapeutics, Inc , announced today its joint venture partner, GMP Biotechnology Limited’s wholly owned subsidiary – Sapu Bioscience, LLC ,...
Source: marketscreener.com
Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update
Presented data from the ongoing ARC-7 Phase 2 trial in non-small cell lung cancer at American Society of Clinical Oncology ; Fc-silent anti-TIGIT monoclonal antibody domvanalimab continued to...
Source: marketscreener.com
A Dab of MAB: Lecanemab, Aducanumab vs Standard of Care Treatment for Alzheimer Disease
Pharmacists play a key role in the management of modern monoclonal antibody treatments for Alzheimer disease.
Source: pharmacytimes.com
Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1
VEVYE® is the First and Only Cyclosporine-Based Product Indicated for the Treatment of Both Signs and Symptoms of Dry Eye Disease with Efficacy Demonstrated After Four WeeksVEVYE® is the Only Water-Free Ophthalmic Product with Convenient Twice-Daily (BID) DosingNASHVILLE, Tenn. & HEIDELBERG, Germany--(BUSINESS WIRE)...
Source: pharmiweb.com